22/05/2024
Today, on May 22nd, MirZyme Therapeutics joins the global community in observing Preeclampsia Awareness Day, an occasion to shed light on a condition that profoundly impacts the lives of millions of women and infants worldwide.
Preeclampsia is a hypertensive disorder that typically occurs after the 20th week of pregnancy, characterised by high blood pressure and often signs of damage to another organ system, most commonly the liver and kidneys. This condition affects approximately 5-8% of pregnancies globally, making it a significant concern in maternal health.
Beyond its immediate health implications, preeclampsia can have long-term effects on both mothers and infants. For women, it increases the risk of cardiovascular disease later in life, while infants born to mothers with preeclampsia are more likely to be premature and have low birth weights, which can lead to a host of health complications. Furthermore, the economic burden of managing preeclampsia and its associated complications extends to healthcare systems and society at large.
At MirZyme Therapeutics, we are committed to make preeclampsia history with our One Test. One Pill. Save Two Lives. By leveraging our patented technology and know-how, we can accurately diagnose and treat preeclampsia, ultimately improving outcomes for mothers and infants. Our dedication to this mission is driven not only by scientific ambition but also by a profound sense of responsibility to the women and families affected by this condition.
As we mark Preeclampsia Awareness Day, let us reaffirm our commitment to raising awareness, supporting research, and advocating for policies that prioritise maternal health. Together, we can work to make preeclampsia history.